Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Almac Secures New Metagenomics and Enzyme Discovery Programme with UCL

Published: Wednesday, May 15, 2013
Last Updated: Wednesday, May 15, 2013
Bookmark and Share
The BBRSC Programme combines Chemistry and Biochemical Engineering at UCL with Almac’s Biocatalysis Group.

The Almac biocatalysis group has secured a prestigious BBSRC (Biotechnology and Biological Sciences Research Council) programme with UCL focused specifically on metagenomics and novel enzyme discovery. The R&D work concerned is set to be carried out jointly between Almac and the departments of Biochemical Engineering and Chemistry at UCL, with high level input from two world leaders in the field of biocatalyst discovery and application, Professors John Ward and Helen Hailes.

Dr. Tom Moody, Almac’s Head of Biocatalysis & Isotope Chemistry, commented “This clearly adds further depth to our expertise and complements our recent collaboration with DSM in accessing diverse enzyme collections.”

Professor Ward remarked: “We are very excited to continue working with Almac on this prestigious project, building on many years of collaboration and partnership. Indeed, this project will see our internal capabilities further developed with true industrial needs in our vision.”

The application of biocatalysis technology to the pharmaceutical and fine chemical industries is continuing to grow year on year and this trend is mirrored in the increasing number of synthetic projects being carried out by the biocatalysis group in Almac.

The only limitation of biocatalysis is in the number of diverse enzymes available in a given enzyme class, which dictates both the substrate range and the stereoselectivity observed for a desired chemical transformation. The majority of enzymes used in biocatalysis are derived from microbial sources. However, it is known that only a tiny percentage (as low as 0.1% from soil samples) of bacteria present in an environmental sample can be cultured and isolated.

Metagenomics, a culture-independent technique used to extract the total DNA from an environment, can circumvent this problem and allow access up to 99% of enzyme genes present in environmental samples. Work previously carried out at UCL has allowed a series of metagenomes to be obtained from various unusual sources. The use of bioinformatic tools developed by John Ward with Prof Christine Orengo of the Structural and Molecular Biology department at UCL will allow the metagenomes concerned to be mined for enzymes usable in both synthetic chemistry and synthetic biology projects.

Moody further commented “The need for more diverse enzymes has never been greater and this research programme further emphasises Almac’s commitment to UK research and to biocatalysis development.”

He continued; “The project will mainly focus on transaminase and cytochrome P450s enzymes. We will   identify, clone and express these enzymes before carrying out extensive screening against panels of ‘typical’ pharmaceutical and fine chemical substrates. This should enable us   to identify novel and commercially useful enzyme biocatalysts. As the follow-on step, directed evolution at Almac will enable further development of the lead enzymes concerned.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac Group Drives Biocatalysis Leadership with a Further $7M Investment
The investment will help develop biocatalysts for scale-up chemistry.
Friday, February 20, 2015
Almac and ESMS Global Collaborate to Offer Unique Clinical Trial Support
Sponsors requesting 24/7 medical support & emergency unblinding can save time and money.
Friday, November 28, 2014
Almac Announces Launch of CLIA Validated Next Generation Sequencing Assay
P53 considered important biomarker for cancer drug discovery.
Thursday, November 13, 2014
Almac Introduce Flexible Clinical Trial Direct to Patient Solution
Available for clinical studies conducted throughout the US & Canada.
Friday, October 31, 2014
Almac Expand its UK Commercial Packaging Facility
Company makes further significant co-investment to meet Japanese client demand for humidity controlled blister packaging.
Friday, October 10, 2014
Almac Forms Academia-Industry Collaboration
Collaboration aims to bring a novel chemical produced via an enzymatic route from under-utilised natural oil to the market.
Friday, September 19, 2014
Almac’s AADx Gene Expression Marker Attracts Significant Commercial Interest from Pharma
Evaluation in colorectal, breast and lung cancer to follow.
Thursday, June 26, 2014
Almac Profits Up 30%
Company will open a new clinical trial secondary packaging facility in Singapore.
Wednesday, May 28, 2014
Almac’s Diagnostics Business Unit Receives NY State Clinical Laboratory Permit
The Permit for trial enrichment and companion diagnostics development allows them to receive patient samples for clinical testing in New York.
Tuesday, April 15, 2014
Almac Achieves Double Success at Business Award Ceremony
Presented with both Excellence in Innovation & Technology.
Tuesday, April 01, 2014
Almac Expands Asia Pacific Operations
Comprehensive support for trials of any size or complexity whether they originate in Asia or include Asian sites.
Wednesday, March 12, 2014
Almac Wins Laboratory Team of the Year at The Irish Laboratory Awards 2013
The awards held to recognize the success and achievements of Ireland’s internationally renowned scientists.
Thursday, December 12, 2013
Almac Announces Release of Enhanced 3PL Customer Billing Application
Company further enhance 3rd Party Logistics commercial support services for niche / orphan drugs.
Tuesday, November 19, 2013
Almac Increase Global Stability Storage Capacity
Company has completed a $2m investment programme.
Tuesday, November 05, 2013
Richard Segiel, Jr. Joins Almac as Vice President of US Business Development
Richard will focus on developing new business, maintaining existing business, and developing partnerships.
Wednesday, October 30, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!